Should You Buy Alibaba Stock Despite the Risks?
Markets rebounded slightly after U.S. President Donald Trump announced a…
Buy
89
TMDX Quote, Financials, Valuation and Earnings
Last price:
$94.14
Seasonality move
:
28.46%
Day range:
$91.39 - $95.90
52-week range:
$55.00 - $177.37
Dividend yield:
0%
P/E ratio:
91.34x
P/S ratio:
7.36x
P/B ratio:
13.58x
Volume:
1.2M
Avg. volume:
1M
1-year change:
1.82%
Market cap:
$3.1B
Revenue:
$441.5M
EPS (TTM):
$1.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TMDX
TransMedics Group
|
$123.4M | $0.24 | 27.41% | -31.06% | $103.14 |
|
AXGN
Axogen
|
$48.3M | $0.02 | 16.84% | -76% | $25.71 |
|
ELMD
Electromed
|
$15.8M | -- | 13.91% | -- | $37.00 |
|
IRIX
IRIDEX
|
$12.8M | -$0.12 | -2.72% | -18.18% | -- |
|
MYO
Myomo
|
$9.2M | -$0.08 | 145.61% | -24% | $9.25 |
|
STXS
Stereotaxis
|
$6.9M | -$0.07 | -0.07% | -20.83% | $4.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TMDX
TransMedics Group
|
$92.25 | $103.14 | $3.1B | 91.34x | $0.00 | 0% | 7.36x |
|
AXGN
Axogen
|
$15.62 | $25.71 | $692.7M | -- | $0.00 | 0% | 3.69x |
|
ELMD
Electromed
|
$22.81 | $37.00 | $195.2M | 30.41x | $0.00 | 0% | 3.43x |
|
IRIX
IRIDEX
|
$1.22 | -- | $20.3M | -- | $0.00 | 0% | 0.41x |
|
MYO
Myomo
|
$4.65 | $9.25 | $159.9M | -- | $0.00 | 0% | 5.39x |
|
STXS
Stereotaxis
|
$1.95 | $4.50 | $167.7M | -- | $0.00 | 0% | 6.17x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TMDX
TransMedics Group
|
69.02% | 2.597 | 24.3% | 7.25x |
|
AXGN
Axogen
|
31.37% | 1.669 | 6.53% | 1.88x |
|
ELMD
Electromed
|
-- | 1.939 | -- | 4.68x |
|
IRIX
IRIDEX
|
51.25% | 1.717 | 9.47% | 0.73x |
|
MYO
Myomo
|
-- | 2.090 | -- | 2.82x |
|
STXS
Stereotaxis
|
-- | 1.683 | -- | 0.74x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TMDX
TransMedics Group
|
$72M | $8.6M | 5.12% | 19.17% | 8.68% | $6.1M |
|
AXGN
Axogen
|
$37.6M | $2M | -6.89% | -10.21% | 4.56% | $7.9M |
|
ELMD
Electromed
|
$12.6M | $2.5M | 15.91% | 15.91% | 15.64% | $2.9M |
|
IRIX
IRIDEX
|
$4.3M | -$1.9M | -146.36% | -157.91% | -16.15% | -$3.1M |
|
MYO
Myomo
|
$8.6M | -$245.3K | -48.64% | -48.64% | -2.03% | $2.5M |
|
STXS
Stereotaxis
|
$3.2M | -$7.6M | -139.2% | -139.2% | -120.3% | $1.3M |
TransMedics Group vs. Competitors
-
Which has Higher Returns TMDX or AXGN?
Axogen has a net margin of 5.64% compared to TransMedics Group's net margin of 0.91%. TransMedics Group's return on equity of 19.17% beat Axogen's return on equity of -10.21%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M AXGNAxogen76.06% $0.01 $151.4M -
What do Analysts Say About TMDX or AXGN?
TransMedics Group has a consensus price target of $103.14, signalling upside risk potential of 11.81%. On the other hand Axogen has an analysts' consensus of $25.71 which suggests that it could grow by 64.62%. Given that Axogen has higher upside potential than TransMedics Group, analysts believe Axogen is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 AXGNAxogen5 0 0 -
Is TMDX or AXGN More Risky?
TransMedics Group has a beta of 2.138, which suggesting that the stock is 113.849% more volatile than S&P 500. In comparison Axogen has a beta of 0.995, suggesting its less volatile than the S&P 500 by 0.462%.
-
Which is a Better Dividend Stock TMDX or AXGN?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or AXGN?
TransMedics Group quarterly revenues are $121.6M, which are larger than Axogen quarterly revenues of $49.4M. TransMedics Group's net income of $6.9M is higher than Axogen's net income of $450K. Notably, TransMedics Group's price-to-earnings ratio is 91.34x while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 7.36x versus 3.69x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group7.36x 91.34x $121.6M $6.9M AXGNAxogen3.69x -- $49.4M $450K
-
Which has Higher Returns TMDX or ELMD?
Electromed has a net margin of 5.64% compared to TransMedics Group's net margin of 12.11%. TransMedics Group's return on equity of 19.17% beat Electromed's return on equity of 15.91%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M ELMDElectromed77.68% $0.22 $43.6M -
What do Analysts Say About TMDX or ELMD?
TransMedics Group has a consensus price target of $103.14, signalling upside risk potential of 11.81%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 62.21%. Given that Electromed has higher upside potential than TransMedics Group, analysts believe Electromed is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 ELMDElectromed2 0 0 -
Is TMDX or ELMD More Risky?
TransMedics Group has a beta of 2.138, which suggesting that the stock is 113.849% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.
-
Which is a Better Dividend Stock TMDX or ELMD?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or ELMD?
TransMedics Group quarterly revenues are $121.6M, which are larger than Electromed quarterly revenues of $16.3M. TransMedics Group's net income of $6.9M is higher than Electromed's net income of $2M. Notably, TransMedics Group's price-to-earnings ratio is 91.34x while Electromed's PE ratio is 30.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 7.36x versus 3.43x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group7.36x 91.34x $121.6M $6.9M ELMDElectromed3.43x 30.41x $16.3M $2M
-
Which has Higher Returns TMDX or IRIX?
IRIDEX has a net margin of 5.64% compared to TransMedics Group's net margin of -16.69%. TransMedics Group's return on equity of 19.17% beat IRIDEX's return on equity of -157.91%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M IRIXIRIDEX37.33% -$0.12 $5.4M -
What do Analysts Say About TMDX or IRIX?
TransMedics Group has a consensus price target of $103.14, signalling upside risk potential of 11.81%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 63.93%. Given that IRIDEX has higher upside potential than TransMedics Group, analysts believe IRIDEX is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 IRIXIRIDEX0 0 0 -
Is TMDX or IRIX More Risky?
TransMedics Group has a beta of 2.138, which suggesting that the stock is 113.849% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.737, suggesting its less volatile than the S&P 500 by 26.316%.
-
Which is a Better Dividend Stock TMDX or IRIX?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or IRIX?
TransMedics Group quarterly revenues are $121.6M, which are larger than IRIDEX quarterly revenues of $11.6M. TransMedics Group's net income of $6.9M is higher than IRIDEX's net income of -$1.9M. Notably, TransMedics Group's price-to-earnings ratio is 91.34x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 7.36x versus 0.41x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group7.36x 91.34x $121.6M $6.9M IRIXIRIDEX0.41x -- $11.6M -$1.9M
-
Which has Higher Returns TMDX or MYO?
Myomo has a net margin of 5.64% compared to TransMedics Group's net margin of -2.16%. TransMedics Group's return on equity of 19.17% beat Myomo's return on equity of -48.64%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M MYOMyomo71.39% -$0.01 $24.7M -
What do Analysts Say About TMDX or MYO?
TransMedics Group has a consensus price target of $103.14, signalling upside risk potential of 11.81%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 98.93%. Given that Myomo has higher upside potential than TransMedics Group, analysts believe Myomo is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 MYOMyomo3 0 0 -
Is TMDX or MYO More Risky?
TransMedics Group has a beta of 2.138, which suggesting that the stock is 113.849% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.
-
Which is a Better Dividend Stock TMDX or MYO?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or MYO?
TransMedics Group quarterly revenues are $121.6M, which are larger than Myomo quarterly revenues of $12.1M. TransMedics Group's net income of $6.9M is higher than Myomo's net income of -$260.1K. Notably, TransMedics Group's price-to-earnings ratio is 91.34x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 7.36x versus 5.39x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group7.36x 91.34x $121.6M $6.9M MYOMyomo5.39x -- $12.1M -$260.1K
-
Which has Higher Returns TMDX or STXS?
Stereotaxis has a net margin of 5.64% compared to TransMedics Group's net margin of -118.53%. TransMedics Group's return on equity of 19.17% beat Stereotaxis's return on equity of -139.2%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M STXSStereotaxis50.73% -$0.09 $11.4M -
What do Analysts Say About TMDX or STXS?
TransMedics Group has a consensus price target of $103.14, signalling upside risk potential of 11.81%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 130.77%. Given that Stereotaxis has higher upside potential than TransMedics Group, analysts believe Stereotaxis is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 STXSStereotaxis2 0 0 -
Is TMDX or STXS More Risky?
TransMedics Group has a beta of 2.138, which suggesting that the stock is 113.849% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.
-
Which is a Better Dividend Stock TMDX or STXS?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or STXS?
TransMedics Group quarterly revenues are $121.6M, which are larger than Stereotaxis quarterly revenues of $6.3M. TransMedics Group's net income of $6.9M is higher than Stereotaxis's net income of -$7.5M. Notably, TransMedics Group's price-to-earnings ratio is 91.34x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 7.36x versus 6.17x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group7.36x 91.34x $121.6M $6.9M STXSStereotaxis6.17x -- $6.3M -$7.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Intel Struggling Against AMD?
Due to its disappointing reports, so-so management, and lack of…
Will PayPal Stock Recover or Keep Sliding?
Payments platform behemoth PayPal Holdings, Inc. (NASDAQ:PYPL) is going through…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
49
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Buy
71
PEGA alert for Apr 24
Pegasystems [PEGA] is up 3.13% over the past day.
Buy
67
SMMT alert for Apr 24
Summit Therapeutics [SMMT] is up 10.38% over the past day.
Sell
36
ENPH alert for Apr 24
Enphase Energy [ENPH] is up 1.44% over the past day.
